Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBT (2019 - 2025)

Historic EBT for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to -$2.0 million.

  • Eton Pharmaceuticals' EBT fell 49021.96% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 2218.24%. This contributed to the annual value of -$3.8 million for FY2024, which is 45268.51% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' EBT is -$2.0 million, which was down 49021.96% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' EBT registered a high of $5.1 million during Q1 2021, and its lowest value of -$6.1 million during Q3 2021.
  • For the 5-year period, Eton Pharmaceuticals' EBT averaged around -$1.1 million, with its median value being -$1.6 million (2022).
  • Per our database at Business Quant, Eton Pharmaceuticals' EBT surged by 39261.87% in 2023 and then plummeted by 49021.96% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' EBT (Quarter) stood at $1.0 million in 2021, then decreased by 12.22% to $912000.0 in 2022, then tumbled by 320.29% to -$2.0 million in 2023, then soared by 74.56% to -$511000.0 in 2024, then tumbled by 282.58% to -$2.0 million in 2025.
  • Its EBT stands at -$2.0 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$1.5 million for Q1 2025.